Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.

Frontiers in immunology - 1 Jan 2021

Jiang Jiehan, Jin Zheng, Zhang Yiqun, Peng Ling, Zhang Yue, Zhu Zhiruo, Wang Yaohui, Tong De, Yang Yining, Wang Jianfei, Yang Yadong, Xiao Kui

Abstract excerpt

Background: The development of immune checkpoint inhibitors (ICIs) is a revolutionary milestone in the field of immune-oncology. However, the low response rate is the major problem of ICI treatment. The recent studies showed that response rate to single-agent programmed cell death protein 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) inhibition in unselected non-small cell lung cancer (NSCLC) patients is 25% so...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Neoplastic

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy

Share to Models, Immunological

Share to Programmed Cell Death 1 Receptor

Share to Survival Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 33927719
DOI: 10.3389/fimmu.2021.646874
PMCID: PMC8076602

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.PMID 33927719Read ↗

A Combination of Biomarkers Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Biomarker analyses to predict benefit of immune checkpoint inhibitors for EGFR-mutated non-small cell lung cancer.Semantic proximity Read ↗

Immunotherapy in advanced non-small-cell lung cancer with EGFR mutations.Semantic proximity Read ↗

The Role of ERBB4 Mutations in the Prognosis of Advanced Non-small Cell Lung Cancer Treated With Immune Checkpoint InhibitorsSemantic proximity Read ↗

Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.Semantic proximity Read ↗

The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.Semantic proximity Read ↗

A Predictive Model for Evaluating Efficacy of Immunotherapy in Non-small-cell Lung Cancer PatientsSemantic proximity Read ↗

Unveiling the influence of tumor and immune signatures on immune checkpoint therapy in advanced lung cancerSemantic proximity Read ↗

The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non-small cell lung cancer patients with epidermal growth factor receptor mutation.Semantic proximity Read ↗

Predicting Durable Responses to Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer Using a Multi-Feature Model.Semantic proximity Read ↗

Prediction of 2-Year Mortality in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors Based on a Machine Learning AlgorithmSemantic proximity Read ↗

Prediction performance comparison of biomarkers for response to immune checkpoint inhibitors in advanced non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.